PRESS RELEASES

Date Title and Summary View
Feb 28, 2014
Summary ToggleZafgen Announces Support of NORD in Observing Rare Disease Day Summary ToggleZafgen Announces Support of NORD in Observing Rare Disease Day
Jan 15, 2014
Summary ToggleZafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome

Beloranib trial demonstrates improvements in body composition and cardiovascular risk factors in the largest placebo-controlled, double-blind, randomized multiple dose trial performed for obesity to date in patients with Prader-Willi syndrome

Summary ToggleZafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Jan 9, 2014
Summary ToggleZafgen Appoints Chief Commercial Officer and New Member of Board of Directors

- Industry Veterans Bring a Wealth of Commercial and Business Development Experience -

Summary ToggleZafgen Appoints Chief Commercial Officer and New Member of Board of Directors
Dec 4, 2013
Summary ToggleZafgen Secures $45 Million in Series E Financing

- Proceeds to Advance Development of Obesity Therapeutic Beloranib -

Summary ToggleZafgen Secures $45 Million in Series E Financing
Nov 15, 2013
Summary ToggleZafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013

Final Study Results Demonstrate Treatment with Beloranib Led to Significant Weight Loss and Improvements in Multiple Cardiometabolic Risk Factors in 147 Obese Subjects

Summary ToggleZafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
Jun 22, 2013
Summary ToggleZafgen Announces New Body Weight Loss and Cardiometabolic Data from Phase 2 Study of Beloranib in Obesity at American Diabetes Association’s 73rd Scientific Sessions®

Interim Results Show Treatment with Beloranib Resulted in Clinically Meaningful Body Weight Loss and Improvements in Multiple Cardiometabolic Risk Factors in Severely Obese Subjects

Summary ToggleZafgen Announces New Body Weight Loss and Cardiometabolic Data from Phase 2 Study of Beloranib in Obesity at American Diabetes Association’s 73rd Scientific Sessions®
Jan 4, 2013
Summary ToggleZafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as Chief Financial Officer

Ms. Allen Brings Significant Public Company Experience as Zafgen Continues to Evaluate its Strategic Options

Summary ToggleZafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as Chief Financial Officer
Dec 4, 2012
Summary ToggleZafgen Secures $21 Million in Series D Financing

Alta Partners Joins Investor Syndicate to Lead New Funding<br /><br />Proceeds to Advance Development of Obesity Therapeutic Beloranib

Summary ToggleZafgen Secures $21 Million in Series D Financing
Nov 6, 2012
Summary ToggleZafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity Summary ToggleZafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
Sep 22, 2012
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society

Findings Show Treatment with Beloranib Resulted in Rapid Weight Loss, Corresponding Reductions in Multiple Cardiovascular Risk Factors in Severely Obese Subjects

Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society